磷酸化蛋白激酶和人类端粒反转录酶在上皮性卵巢癌中的表达及临床意义

doi:10.3760/cma.j.issn.1673422X.2017.09.006

摘要/Abstract

摘要： 目的探讨磷酸化蛋白激酶B1（pAkt1）和人类端粒反转录酶（hTERT）在上皮性卵巢癌中的表达及其对预后的影响。方法采用免疫组织化学SP法检测72例上皮性卵巢癌组织和10例正常卵巢组织中hTERT和pAkt1蛋白的表达，分析pAkt1、hTERT蛋白表达的相关性及其与临床病理特征和临床预后的关系。结果上皮性卵巢癌组织pAkt1阳性表达率为73.6%，hTERT阳性表达率为56.9%，与正常卵巢组织相比差异均有统计学意义（χ2=20.814,P<0.001; χ2=11.389,P<0.001）。pAkt1、hTERT蛋白在上皮性卵巢癌中表达无关（r=0.075,P=0.532）；pAkt1、hTERT蛋白表达与患者肿瘤病理分化程度相关（χ2=6.475,P=0.011;χ2=1.370，P=0.001）；pAkt1和hTERT蛋白同时阳性表达的患者无瘤生存期明显短于非共同表述患者(8.585个月∶11.227个月，χ2=4.361，P=0.037），但总生存期差异无统计学意义（11.107个月∶11.695个月, χ2=0.394,P=0.530）。结论pAkt1和hTERT蛋白在上皮性卵巢癌中高表达，pAkt1和hTERT蛋白同时高表达提示上皮性卵巢癌患者预后较差。

关键词: 卵巢肿瘤, 磷酸化蛋白激酶B1, 人类端粒反转录酶

Abstract: ObjectiveTo evaluate the expressions and prognostic significance of phosphorylation of protein kinase B1 (pAkt1) and human telomere reverse transcriptase (hTERT) in epithelial ovarian carcinoma. MethodsThe expressions of pAkt1 and hTERT were examined by immunohistochemical SP method in 72 cases of epithelial ovarian carcinoma and 10 normal endometrial tissues to analyze the correlation between pAkt1 and hTERT and their relationships with clinicpathological features and prognosis. ResultsThe positive expression rate of pAkt1 in epithelial ovarian carcinoma was 73.6%, and the positive expression rate of hTERT was 56.9%， compared with normal ovarian tissues, with statistical significance (χ2=20.814, P<0.001; χ2=11.389, P<0.001).The expression of pAkt1 was not associated with hTERT expression (r=0.075, P=0.532) in epithelial ovarian carcinoma. The expressions of pAkt1 and hTERT in epithelial ovarian carcinoma were correlated with tumor differentiation status (χ2=6.475, P=0.011; χ2=1.370, P=0.001). The diseasefree survival of patients with pAkt1 and hTERT positive coexpression was significantly shorter than others (8.585 months vs. 11.227 months, χ2=4.361, P=0.037), but there was no significant difference in overall survival (11.107 months∶11.695 months, χ2=0.394, P=0.530). ConclusionpAkt1 and hTERT are highly expressed in epithelial ovarian carcinoma, and high coexpression of pAkt1 and hTERT indicates poor prognosis in epithelial ovarian carcinoma.

Key words: Ovarian neoplasms, Phosphorylation of protein kinase B1, Human telomere reverse transcriptase

刘则烨, 胡静, 冯玉环. 磷酸化蛋白激酶和人类端粒反转录酶在上皮性卵巢癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2017, 44(8): 668-671.

LIU Ze-Ye, HU Jing, FENG Yu-Huan. Expressions and clinical significance of pAkt1 and hTERT in epithelial ovarian carcinoma[J]. Journal of International Oncology, 2017, 44(8): 668-671.

参考文献

［1］张海燕，孙红. Akt基因在上皮性卵巢癌组织中的表达及临床意义［J］. 现代妇产科进展, 2014, 23(12): 964967. DOI: 10.13283/j.cnki.xdfckjz.2014.12.013. ［2］ Ramlee MK, Wang J, Toh WX, et al. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene［J］. Genes (Basel), 2016, 7(8): E50. DOI: 10.3390/genes7080050. ［3］ Shay JW. Role of telomeres and telomerase in aging and cancer［J］. Cancer Discov, 2016, 6(6): 584593. DOI: 10.1158/21598290.CD160062. ［4］庄志明, 林天旗, 林建贵, 等. 靶向沉默Notch1基因对肾透明细胞癌增殖、凋亡及Akt/mTOR信号通路的影响［J］. 中华泌尿外科杂志, 2017, 38(2): 136140. DOI: 10.3760/cma.j.issn.10006702.2017.02.016. ［5］关长群, 吴秀娟, 普雄明, 等. 微RNA126介导磷脂酰肌醇3激酶调节亚基2及磷脂酰肌醇3激酶/蛋白激酶B信号与肿瘤关系的新进展［J］. 医学综述, 2016, 22(19): 37953797, 3798. DOI: 10.3969/j.issn.10062084.2016.19.014. ［6］ Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of highgrade serous ovarian carcinoma［J］. J Clin Invest, 2013, 123(1): 517525. DOI: 10.1172/JCI65833. ［7］ GarciaDios DA, Lambrechts D, Coenegrachts L, et al. Highthroughput interrogation of PIK3CA, PTEN, KＲAS, FBXW7 and TP53 mutations in primary endometrial carcinoma［J］. Gynecol Oncol, 2013, 128(2): 327334. DOI: 10.1016/j.ygyno.2012.11.037. ［8］ Cohen MM Jr. The AKT genes and their roles in various disorders［J］. Am J Med Genet A, 2013, 161A(12): 29312937. DOI: 10.1002/ajmg.a.36101. ［9］ Avan A, Narayan R, Giovannetti E, et al. Role of Akt signaling in resistance to DNAtargeted therapy［J］. World J Clin Oncol, 2016, 7(5): 352369. ［10］ Jia W, Chang B, Sun L, et al. REDD1 and pAKT overexpression may predict poor prognosis in ovarian cancer［J］. Int J Clin Exp Pathol, 2014, 7(9): 59405949. ［11］ Rahman M, Nakayama K, Rahman MT. et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma［J］. Hum Pathol, 2012, 43(12): 21972206. DOI: 10.1016/j.humpath.2012.03.011. ［12］冯玉环, 易建平, 陈莹, 等. 磷酸化蛋白激酶B1和人端粒酶反转录酶在卵巢上皮性癌中的表达及其临床意义［J］. 肿瘤研究与临床, 2017, 29(6): 378381. DOI: 10.3760/cma.j.issn.10069801.2017.06.005. ［13］邹存华, 王宏, 宋冬冬, 等. P38MAPK信号通路与uPA在卵巢癌细胞及组织中表达的相关性［J］. 中国癌症杂志, 2015, (8): 572578. DOI: 10.3969/j.issn.10073969.2015.08.003. ［14］ Sasaki T, Kuniyasu H, Luo Y. et al. AKT activation and telomerase reverse transcriptase expression are concurrently associated with prognosis of gastric cancer［J］. Pathobiology, 2014, 81(1): 3641. DOI: 10.1159/000351721.

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[3]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[4]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[5]	李晨曦, 赵宏伟. PARP抑制剂治疗铂耐药卵巢癌的研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 180-183.
[6]	李哲丰, 李洁, 赵晓婷, 岳文涛. GLDC通过PI3K/Akt/mTOR通路调控卵巢癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2021, 48(12): 716-722.
[7]	关若丹, 摘译. 奥拉帕利对携带BRCA突变的新诊断晚期卵巢癌、原发性腹膜癌、输卵管癌患者维持治疗的有效性研究:SOLO1试验的亚组分析(摘译)[J]. 国际肿瘤学杂志, 2021, 48(12): 764-768.
[8]	郑静, 姚胜, 沈文洁, 孙志佳, 赵辉, 付艳, 高珂, 杜楠. 腹腔灌注贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗卵巢癌所致癌性腹腔粘连的临床探讨[J]. 国际肿瘤学杂志, 2021, 48(11): 660-665.
[9]	杨立芬, 宋伟, 许大伟, 武军, 高然. miR-103a-3p/CHI3L1在卵巢癌细胞增殖和血管拟生中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(6): 333-339.
[10]	薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[11]	杨怡婷, 程忠平. 炎症细胞因子在卵巢上皮癌化疗耐药中的作用[J]. 国际肿瘤学杂志, 2020, 47(4): 249-251.
[12]	樊阳阳, 王影, 袁峰, 杜善平, 贺荣荣, 加燕. MALAT1靶向miR-142-3p在卵巢癌化疗耐药中的机制研究[J]. 国际肿瘤学杂志, 2020, 47(2): 82-89.
[13]	权瑞泉, 张丽, 匡黎, 李洪波, 肖梅仙. 奥拉帕尼联合贝伐珠单抗治疗复发性铂类敏感卵巢癌患者的疗效及对血清HE4、CA125、CTC水平的影响[J]. 国际肿瘤学杂志, 2020, 47(10): 606-610.
[14]	唐南敏, 于占彩. 转化生长因子-β通路与卵巢癌靶向治疗[J]. 国际肿瘤学杂志, 2019, 46(9): 562-565.
[15]	褚超男,黄琪. 脂质体多柔比星单药与吉西他滨联合奥沙利铂对复发性铂耐药卵巢癌患者的疗效及安全性比较[J]. 国际肿瘤学杂志, 2019, 46(1): 32-35.